

Macroplastique®

BULKING AGENT

Treatment of Male Stress Urinary Incontinence

Macroplastique is indicated for SUI often found in men following TURP or Radical Prostatectomy.

- » Demonstrated safety and efficacy
- » Minimally invasive procedure
- » Immediate results



Minimally Invasive


- » Significantly less invasive than the alternative treatment options
- » Provides immediate relief of symptoms
- » Fast recovery and minimal complications

Proven


- » Clinical success since 1991
- » Documented long-term success¹⁻⁷
 - Up to 5 year follow-up
 - Up to 80% success determined by urine loss (pad weight), reduction in pad usage, and assessment of patients' perception of the outcome of therapy

Cost Effective

Significantly less expensive than current alternative treatment methods.



Long-Term Success (Cured and Improved)



“There was an overall perceived [patient] satisfaction of 80%”⁴

Macroplastique®

BULKING AGENT



Product Information

Catalog Number	Product Description	Procedure Requirements
MPQ-2.5	Macroplastique Implants 2.5 ml unit	3 units
AD	Reusable Control Flow Administration Device Includes syringe adapter	1 device
MRN-018	Rigid Endoscopic Needle - Adult 5 Fr. shaft x 380 mm long with 18 gauge tip x 14 mm long	1 needle
MFN-718	Flexible Endoscopic Needle - Adult 7 Fr. shaft x 400 mm long with 18 gauge tip x 10 mm long	1 needle

1. Arya, M., Hamid, R., Sharon, A., & Shah, P. (2002). The treatment of male stress incontinence in neuropathic bladders with polydimethylsiloxane. Proceedings ICS Annual Meeting, Heidelberg, Germany, August 28-30, 230.
2. Hamid, R., Arya, M., Khastgir, J., Patel, H., & Shah, P. (2003). The treatment of male stress urinary incontinence with polydimethylsiloxane in compliant bladders following spinal cord injury. *Spinal Cord*, 41, 286-289.
3. Pinggera, G.M., Furtmüller, B., Rehder, P., Fiala, H.R., Bartch, G., & Strasser, H. (2003). Submucosale blasenhalsunterspritzung mit Macroplastique® in der behandlung der stressinkontinenz nach radikaler prostatektomie. *Wiener Klin Wochenschrift. Middle Eur J Med*, 115(Suppl 1).
4. Khastgir, J.N., & Shah, P.J.R. (2000). Macroplastique™ injections: How effective is it for stress incontinence in males? Proceedings ICS Annual Meeting, Tampere, Finland, August 28-31.
5. Herschorn, S., & Buencamino, D. (2002). Early results of intraurethral Macroplastique for post radical prostatectomy. *Neuro Urodyn*, 21(4), 332.
6. Mourad, S. (2003). Long term efficacy of Macroplastique injection for the treatment of urinary incontinence in males and females. *Europ Urol Supplements*, 2(1), 175.
7. Kylmäjä, T., Tainio, H., Raitanen, M., Teuvo, L.J., & Tammela, T.L. (2003). Treatment of postoperative male urinary incontinence using transurethral Macroplastique injections. *J Endourol*, 17(2), 113-115.

For complete instructions for use, storage, warnings, indications, contraindications, precautions, adverse reactions and disclaimer of warranties, please refer to the insert accompanying each Macroplastique or online at www.cogentixmedical.com. Models are for illustrative purpose only. Macroplastique is a registered trademark. Macroplastique is manufactured by Uroplasty LLC. ©2015 Cogentix Medical. All rights reserved. 55004C 11/16

Cogentix
Medical

cogentixmedical.com



Hofkamp 2,
6161 DC Geleen
The Netherlands

TEL +31 (0)88.423.79.20
info.holland@cogentixmedical.com

Manchester Business Park
3000 Aviator Way
Manchester M22 5TG

TEL 0800.032.5964
info.uk@cogentixmedical.com